We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Efficacy and safety of once‐weekly dulaglutide in adult Chinese patients with type 2 diabetes and lower baseline body mass index.
- Authors
Shi, Yongquan; Liu, Siying; Zhu, Jiankun; Hong, Tianpei
- Abstract
Glycemic control Similar to patients with baseline BMI >=25 kg/m SP 2 sp , patients with baseline BMI <25 kg/m SP 2 sp demonstrated significant HbA1c reduction following 26-week treatment with dulaglutide 1.5 and 0.75 mg (Figure 1A). Keywords: body mass index; dulaglutide; type 2 diabetes; ; ; 2 EN body mass index dulaglutide type 2 diabetes ZH 2 353 357 5 03/03/21 20210401 NES 210401 GLO:55QH/01apr21:jdb13147-toc-0001.jpg PHOTO (COLOR): . gl B Highlights b In Chinese patients with type 2 diabetes (T2D) and body mass index (BMI) <25 kg/m SP 2 sp , dulaglutide demonstrated great improvements in glycemic control with mild body weight reduction and low hypoglycemia risk. The results indicate that dulaglutide is effective and safe in patients with T2D and lower BMI; therefore, BMI should not be a consideration when dulaglutide is prescribed to Chinese patients with T2D. Changes in HbA1c (Supp 1A) and body weight (Supp 1B) from baseline at week 26 by different baseline BMI categories (BMI <24; 24 <= BMI <28; 28 <= BMI <30; BMI >=30 kg/m2).
- Subjects
BODY mass index; TYPE 2 diabetes; DRUG efficacy
- Publication
Journal of Diabetes, 2021, Vol 13, Issue 4, p353
- ISSN
1753-0393
- Publication type
Article
- DOI
10.1111/1753-0407.13147